Creative Planning
NRIX icon

Creative Planning’s Nurix Therapeutics NRIX Stock Holding History

Creative Planning’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
25,070
+5,949
+31% +$101K ﹤0.01% 3052
2026
Q1 		$296K Buy
19,121
+1,017
+6% +$16.9K ﹤0.01% 3436
2025
Q4 		$343K Buy
18,104
+7,070
+64% +$102K ﹤0.01% 3152
2025
Q3 		$102K Sell
11,034
-5,375
-33% -$55.8K ﹤0.01% 3667
2025
Q2 		$187K Buy
+16,409
New +$177K ﹤0.01% 3247
2025
Q1 		– Sell
-1,028
Closed -$19.4K – 3649
2024
Q4 		$19.4K Buy
+1,028
New +$23.6K ﹤0.01% 3344

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Creative Planning's NRIX Position: Q2 2026 in Review

Creative Planning increased its Nurix Therapeutics (NRIX) stake by 31% in Q2 2026, buying an estimated $101K and bringing the position to 25,070 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Creative Planning first reported a position in NRIX in Q4 2024 and has held it in 6 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Creative Planning held 25,070 shares of Nurix Therapeutics worth $608K as of Q2 2026.
  • Creative Planning bought 5,949 Nurix Therapeutics shares in Q2 2026, an estimated $101K.
  • Nurix Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3052 holding.
  • Creative Planning first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.